Data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS) will be presented during an oral presentation by Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center.
In addition, data from Adaptimmune’s ongoing MAGE‑A10 pilot studies will be presented at a poster session.
Oral presentation of updated MRCLS data:
- Title: Pilot Study of NY-ESO-1c259T Cells in Advanced Myxoid/Round Cell Liposarcoma
- Abstract #: 3005
- Oral session: Developmental Therapeutics—Immunotherapy
Saturday June 2, 2018
4:24 PM– 4:36PM (CDT)
McCormick Place South, Hall B1
Poster presenting MAGE-A10 safety data
- Title: Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials
- Abstract #: 3056
- Poster session: Developmental Therapeutics—Immunotherapy
Monday June 4, 2018
8:00 AM-11:30 AM (CDT)
McCormick Place South, Hall A
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report filed on form 10-Q with the
Sébastien Desprez – VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
T: +1 215 825 9310
M: +1 215 460 8920
Source: Adaptimmune Therapeutics plc